A renaissance of neural networks in drug discovery by Baskin I. et al.
Expert Opinion on Drug Discovery 2016 vol.11 N8, pages 785-795
A renaissance of neural networks in drug discovery
Baskin I., Winkler D., Tetko I.
Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia
Abstract
© 2016 Informa UK Limited, trading as Taylor & Francis Group.Introduction: Neural networks are
becoming  a  very  popular  method  for  solving  machine  learning  and  artificial  intelligence
problems. The variety of neural network types and their application to drug discovery requires
expert knowledge to choose the most appropriate approach. Areas covered: In this review, the
authors discuss traditional and newly emerging neural network approaches to drug discovery.
Their focus is on backpropagation neural networks and their variants, self-organizing maps and
associated  methods,  and  a  relatively  new  technique,  deep  learning.  The  most  important
technical issues are discussed including overfitting and its prevention through regularization,
ensemble and multitask modeling, model interpretation, and estimation of applicability domain.
Different aspects of using neural networks in drug discovery are considered: building structure-
activity models with respect to various targets; predicting drug selectivity, toxicity profiles,
ADMET and physicochemical properties; characteristics of drug-delivery systems and virtual
screening. Expert opinion: Neural networks continue to grow in importance for drug discovery.
Recent developments in deep learning suggests further improvements may be gained in the
analysis of large chemical data sets. It’s anticipated that neural networks will be more widely
used in drug discovery in the future, and applied in non-traditional areas such as drug delivery
systems, biologically compatible materials, and regenerative medicine.
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